Vetoquinol VETO.PA · EUR

Its shares trade on Euronext Paris under the ticker VETO.PA. It has been listed since 16 November 2006. In the fiscal year to 31 December 2025, it reported revenue of €525.7m and net income of €57.3m. At that date it held total assets of €763.6m and shareholders' equity of €591.4m.

Vétoquinol SA engages in designs, develops and sells veterinary drugs and non-medicinal products. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Matthieu FrechinChairman of the Board, Chief Executive Officer, since 2001€393,733
• Mr. Alain MassonDeputy Chief Executive Officer and Head Pharmacist, Group Quality Director€197,812
• Mr. Dominique DerveauxGroup Chief Operating Officer, since 2020€365,836
• Ms. Nathalie ArlecchiniGroup Human Resources Director
• Mrs. Audrey ChanoinatDirector€21,000
• Mr. M. Luc FrechinDirector€23,100
• Mr. Philippe ArnoldIndependent Director€23,100
• Ms. Marie-Josephe BaudIndependent Director€23,100
• Mr. Louis ChampelIndependent Director€23,100
• Mrs. Anne GraffinIndependent Director€23,100

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.